Evaluating Efficacy and Safety of Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) With Defined BCR-ABL1 Kinase Mutations in Imatinib or Dasatinib

Condition:   CML-CP; Mutation;TKI Interventions:   Drug: Flumatinib;   Drug: Nilotinib Sponsor:   Wuhan Union Hospital, China Recruiting

Source: ClinicalTrials.gov - December 23, 2020 Category: Research Source Type: clinical trials